Filing Details
- Accession Number:
- 0001104659-20-033490
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-13 21:31:50
- Reporting Period:
- 2020-03-09
- Accepted Time:
- 2020-03-13 21:31:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1264587 | Stemline Therapeutics Inc | STML | Pharmaceutical Preparations (2834) | 450522567 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1797467 | Robert Francomano | C/O Stemline Therapeutics, Inc. 750 Lexington Avenue, Eleventh Floor New York NY 10022 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-03-09 | 1,266 | $5.00 | 197,930 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- In connection with the vesting of 3,253 shares on March 8, 2020 a total of 1,266 shares were sold by the Company on March 9, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
- Reflects the weighted average sale price. The range of prices for the shares sold on March 9, 2020 was $5.00 to $5.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
- Of the shares listed, 146,303 shares are restricted stock.
Billionaire Hedge Funds
